AR129556A1 - Compuestos químicos - Google Patents
Compuestos químicosInfo
- Publication number
- AR129556A1 AR129556A1 ARP230101456A ARP230101456A AR129556A1 AR 129556 A1 AR129556 A1 AR 129556A1 AR P230101456 A ARP230101456 A AR P230101456A AR P230101456 A ARP230101456 A AR P230101456A AR 129556 A1 AR129556 A1 AR 129556A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- group
- acceptable salt
- compound
- tautomer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 abstract 2
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
Abstract
Se proporcionan compuestos y composiciones farmacéuticas y usos de estos para inhibir canales de iones sodio dependientes del voltaje Naᵛ1.8 y tratar enfermedades mediadas por Naᵛ1.8, tales como dolor y enfermedades asociadas al dolor, y enfermedades cardiovasculares. Reivindicación 1: Un compuesto seleccionado del grupo que consiste en: el grupo de fórmulas (1), o una sal farmacéuticamente aceptable de este. Reivindicación 8: Un compuesto seleccionado del grupo que consiste en: el grupo de fórmulas (2), o un tautómero de este, o una sal farmacéuticamente aceptable de este. Reivindicación 9: Una composición farmacéutica caracterizada porque comprende el compuesto o sal farmacéuticamente aceptable de este según una cualquiera de las reivindicaciones 1 a 7, y un excipiente farmacéuticamente aceptable. Reivindicación 10: Una composición farmacéutica caracterizada porque comprende el compuesto, o tautómero de este, o sal farmacéuticamente aceptable de este según la reivindicación 8, y un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263350640P | 2022-06-09 | 2022-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129556A1 true AR129556A1 (es) | 2024-09-04 |
Family
ID=87074597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101456A AR129556A1 (es) | 2022-06-09 | 2023-06-07 | Compuestos químicos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230416287A1 (es) |
| EP (1) | EP4536673A1 (es) |
| JP (1) | JP2025519523A (es) |
| KR (1) | KR20250022122A (es) |
| CN (1) | CN119365473A (es) |
| AR (1) | AR129556A1 (es) |
| AU (1) | AU2023284137A1 (es) |
| CA (1) | CA3258570A1 (es) |
| CL (1) | CL2024003739A1 (es) |
| CO (1) | CO2025000063A2 (es) |
| IL (1) | IL317272A (es) |
| MX (1) | MX2024015095A (es) |
| TW (1) | TWI867570B (es) |
| WO (1) | WO2023238064A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201604477SA (en) * | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| US20230103791A1 (en) | 2019-06-27 | 2023-04-06 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors |
-
2023
- 2023-06-07 CA CA3258570A patent/CA3258570A1/en active Pending
- 2023-06-07 CN CN202380045325.9A patent/CN119365473A/zh active Pending
- 2023-06-07 TW TW112121226A patent/TWI867570B/zh active
- 2023-06-07 US US18/330,569 patent/US20230416287A1/en active Pending
- 2023-06-07 WO PCT/IB2023/055886 patent/WO2023238064A1/en not_active Ceased
- 2023-06-07 IL IL317272A patent/IL317272A/en unknown
- 2023-06-07 AU AU2023284137A patent/AU2023284137A1/en active Pending
- 2023-06-07 JP JP2024572227A patent/JP2025519523A/ja active Pending
- 2023-06-07 KR KR1020257000195A patent/KR20250022122A/ko active Pending
- 2023-06-07 AR ARP230101456A patent/AR129556A1/es unknown
- 2023-06-07 EP EP23736841.0A patent/EP4536673A1/en active Pending
-
2024
- 2024-12-05 MX MX2024015095A patent/MX2024015095A/es unknown
- 2024-12-05 CL CL2024003739A patent/CL2024003739A1/es unknown
-
2025
- 2025-01-07 CO CONC2025/0000063A patent/CO2025000063A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025519523A (ja) | 2025-06-26 |
| WO2023238064A1 (en) | 2023-12-14 |
| CL2024003739A1 (es) | 2025-04-21 |
| TW202415383A (zh) | 2024-04-16 |
| KR20250022122A (ko) | 2025-02-14 |
| AU2023284137A1 (en) | 2024-12-05 |
| CO2025000063A2 (es) | 2025-01-23 |
| EP4536673A1 (en) | 2025-04-16 |
| CA3258570A1 (en) | 2023-12-14 |
| TWI867570B (zh) | 2024-12-21 |
| CN119365473A (zh) | 2025-01-24 |
| US20230416287A1 (en) | 2023-12-28 |
| MX2024015095A (es) | 2025-01-09 |
| IL317272A (en) | 2025-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| AR126701A1 (es) | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos | |
| CO2022017903A2 (es) | Compuestos de dihidroquinolinsulfonamida de ciclobutilo | |
| CL2025001072A1 (es) | Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer. | |
| CO2022004594A2 (es) | Oxinitruro de piridina, método para su preparación y uso de este | |
| PE20241127A1 (es) | Compuestos triciclicos como inhibidores de kras | |
| WO2018045084A1 (en) | Tetracycline compounds and methods of treatment | |
| MX2021014913A (es) | Compuestos de pirrolidina. | |
| CR20230132A (es) | Inhibidores de apol1 y métodos para usar los mismos | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| CL2023000670A1 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 | |
| BR112022013488A2 (pt) | Pirazolo-pirimidinas substituídas e seu uso | |
| UY39799A (es) | Compuestos de pirrolil–sulfonamida | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr | |
| PE20251401A1 (es) | Inhibidores de topoisomerasa-1 derivados de exatecan composiciones farmaceuticas y sus usos | |
| UY39681A (es) | Derivados de ciclobutilo 1,3–sustituidos y sus usos | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| AR129556A1 (es) | Compuestos químicos | |
| CR20250124A (es) | Compuestos para el tratamiento del cáncer | |
| CR20250141A (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| AR128998A1 (es) | Compuestos químicos | |
| DOP2025000235A (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| PE20241171A1 (es) | Composicion farmaceutica para prevenir o tratar la fibrosis |